Haleon was spun off from GSK amid investor pressure, showing steady growth but facing debt concerns. See more about HLN stock ...

The US Food and Drug Administration has proposed to remove oral phenylephrine, widely used in cold and cough syrups.

Mehta said HUL's focus would continue to ensure uninterrupted supplies of COVID relevant portfolio and meeting the demand arising out of evolving consumer needs ...

Phenylephrine:CVS pulls cold medicines with the ingredient Companies such as Procter & Gamble and GSK were among several accused ... or remove such drugs from the market. The Consumer Healthcare ...

GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...

WASHINGTON — Pharmaceutical industry giant GSK plans to depart the biotechnology industry’s largest trade group, the ...

Haleon backed its full-year guidance despite lower third-quarter revenue and earnings, although organic revenue growth of 6.1% topped its own forecasts.

GlaxoSmithKline ranks as one of the largest companies by total sales. The company wields its might across several therapeutic classes, including respiratory, oncology, and antiviral, as well as ...

GlaxoSmithKline (GSK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham ...

GSK has received approval for its vaccine, AREXVY, in Canada to prevent LRTD caused by RSV in adults aged 50 to 59 years.

GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...

Total sales of £8 billion for the three months were 2% lower than a year ago, although 2% higher when excluding currency ...